MB 107 - March Biosciences
Alternative Names: MB-107 - March BiosciencesLatest Information Update: 18 Jan 2024
At a glance
- Originator March Biosciences
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Precursor T-cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Preclinical Cancer; Unspecified
Most Recent Events
- 04 Dec 2023 Phase-I clinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma (Parenteral) (March Biosciences pipeline, December 2023)
- 04 Dec 2023 Phase-I clinical trials in T-cell lymphoma (Parenteral) (March Biosciences pipeline, December 2023)
- 04 Dec 2023 Preclinical trials in Cancer in USA (Parenteral) (March Biosciences pipeline, December 2023)